TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07221669: An Open-Label Study to Assess the Efficacy and Safety of Multiple Doses of Salanersen (BIIB115) Delivered Intrathecally to Treatment-Naïve, Presymptomatic Infants With Genetically Diagnosed Spinal Muscular Atrophy

Sponsor: Biogen · Phase: PHASE3 · Area: RARE_ORPHAN · Target Enrollment: 30 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$1,170,080

Rescue Site Savings

+$804,430

Unlock Full NCT07221669 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07221669 Rescue Dossier →